long term effects of glp-1 agonists Frontiers ๐ก New research suggests a
Description
Oral semaglutide in type 2 diabetes
PMCID: PMC10698219
Glucagon is released from the endocrine pancreas in response to a meal and binds to G protein-coupled receptors on skeletal muscle and the liver to exert its glucoregulatory effects
In November 2023, the Food and Drug Administration approved a version for weight loss under the name Zepbound.
